Historical AI Consensus
This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.
- Symbol
- DSY.PAR
- Batch
- 7
- Published
- September 20, 2026
- AI Advisors
- 14
Historical AI Consensus Investment Thesis
Dassault Systemes (DSY) Stock Forecast and AI Rating
Forecast targets and rating
Published batch rating
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY€23
+11.7%+12.2% incl. dividends5-Year
BUY€36
+73.7%+78.1% incl. dividendsPublished batch insight
Mission Critical Engineering Software Trough Unlocks High Margin Cash Flow Compounding
High consensus confirms that mission-critical digital twin switching moats and expanding cloud subscription recurring revenue insulate long-term cash generation. While European automotive capital expenditure contraction and life sciences integration drag create near-term top-line friction, disciplined cost containment and aerospace rearmament backlogs secure durable free cash flow compounding.
This analysis preserves the original published batch. Audit published forecasts in full transparency
Elon Musk (Visionary), Sherlock Holmes (Whistleblower), Universal Investor (Polymath), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), J.P. Morgan (Titan), Warren Buffett (Value Purist), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.
Full published thesis
Executive Summary
If you invested $10,000 in Dassault Systemes at the forecast anchor (2026-09-18): $18,528 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 0.5% net dividend yield for Dassault Systemes.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in EUR; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (EUR) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 21.05 | +2.37% | +2.37% | Fourth-quarter budget allocations support mission-critical enterprise renewals, while management sets pragmatic medium-term cloud targets at Capital Markets Day. Resilient free cash flow conversion confirms the cyclical valuation floor, stabilizing share prices from recent oversold conditions. |
| Q1 2027 | 21.61 | +2.68% | +5.11% | Full-year results demonstrate solid subscription annual run rate progression, though cautious constant-currency guidance and seasonal first-quarter license lulls restrain speculative momentum. Persistent European automotive capital expenditure delays temper broader enthusiasm, keeping quarterly appreciation measured. |
| Q2 2027 | 22.37 | +3.50% | +8.79% | Initial operational consolidation of ArisGlobal stabilizes the Life Sciences division, ending sequential trial booking contractions. Accelerated aerospace and defense contract billings counterbalance ongoing European manufacturing stagnation, generating modest operating margin expansion and investor interest. |
| Q3 2027 | 22.96 | +2.64% | +11.66% | Second-quarter metrics confirm resilient non-IFRS operating margins as cloud migration J-curve friction moderates. Elevated interest rates limit broader multiple expansion, but sticky enterprise maintenance renewals and negligible customer churn maintain solid valuation support across trading desks. |
| Q4 2027 | 23.90 | +4.12% | +16.27% | Year-end software procurement flushes favor multi-year 3DEXPERIENCE cloud migrations, lifting subscription recurring revenue past eighty-three percent of software intake. Strong seasonal operating cash flows confirm fundamental business model durability, spurring gradual equity repricing. |
| Q1 2028 | 24.67 | +3.21% | +20.00% | Audited annual statements confirm steady diluted earnings per share growth and expanding operating cash flow. Management maintains disciplined cost containment, reassuring institutional investors that underlying software profitability easily survives European industrial manufacturing weakness. |
| Q2 2028 | 25.53 | +3.48% | +24.17% | Life Sciences bookings post consistent positive comparisons as biopharmaceutical research spending normalizes. Scaled deployment of virtual twin simulation tools across industrial equipment cohorts generates positive operating leverage, driving consistent institutional accumulation across European bourses. |
| Q3 2028 | 25.99 | +1.81% | +26.42% | Seasonal summer trading lulls and ongoing automotive restructuring headlines cap near-term multiple re-rating. Nevertheless, expanding sovereign defense backlogs and steady SolidWorks subscription upgrades preserve cash-flow compounding, insulating the equity against broader cyclical industrial pullbacks. |
| Q4 2028 | 27.08 | +4.19% | +31.72% | Strong fourth-quarter enterprise software closings drive full-year free cash flow toward 1.7 billion euros. Early monetization of generative engineering design add-ons lifts average revenue per seat, delivering an earnings beat and supporting healthy year-end appreciation. |
| Q1 2029 | 27.84 | +2.81% | +35.42% | Full-year financial reporting confirms the completion of the ratable cloud subscription transition, with recurring revenues providing unmatched earnings visibility. Pragmatic guidance and steady balance-sheet deleveraging reinforce investor conviction in durable, low-volatility per-share compounding. |
| Q2 2029 | 28.72 | +3.15% | +39.68% | Cross-selling between integrated compliance platforms and clinical development expands enterprise contract values. Operational efficiencies from cloud delivery platforms expand operating margins toward target thresholds, prompting selective sell-side upgrades and sustaining constructive equity performance. |
| Q3 2029 | 29.35 | +2.21% | +42.77% | Scheduled legacy bond maturities shift focus toward capital allocation discipline, which management meets via accumulated operating cash flow. Enterprise software renewals remain rock-solid, maintaining steady price appreciation despite broader macroeconomic hesitation across continental Europe. |
| Q4 2029 | 30.37 | +3.47% | +47.73% | Fourth-quarter enterprise contract awards in defense, civil aviation, and maritime digital twins demonstrate strong closing velocity. High cash-flow conversion allows the board to augment shareholder distributions, rewarding patient capital into the calendar year-end. |
| Q1 2030 | 31.18 | +2.67% | +51.67% | Annual financial disclosures validate sustained high-single-digit operating profit expansion on disciplined overhead. The absence of customer defection confirms Dassault's insurmountable technical switching moats, providing a reliable fundamental platform for steady per-share equity appreciation. |
| Q2 2030 | 31.78 | +1.92% | +54.58% | Wider commercialization of autonomous industrial simulation companions across automotive and aerospace accounts lifts software average revenue per user. Operating margins remain stable above historical medians, ensuring steady price gains backed by tangible cash-flow growth. |
| Q3 2030 | 32.45 | +2.10% | +57.83% | Mid-year valuation consolidation reflects mature CAD market penetration, but recurring maintenance fees and cloud subscriptions prevent downward price pressure. Pristine balance-sheet net cash cushions the equity against broader European technology sector volatility. |
| Q4 2030 | 33.47 | +3.16% | +62.82% | Comprehensive multi-year contract renewals across top-tier discrete manufacturing clients deliver strong fourth-quarter cash collections. Market participants increasingly price the business as an indispensable, cash-generative industrial software utility, prompting steady institutional buying interest. |
| Q1 2031 | 34.20 | +2.17% | +66.35% | Audited full-year results confirm operating margins sustaining at targeted long-term levels, supported by programmatic anti-dilutive share repurchases. Compounding earnings per share outpace sluggish broader industrial manufacturing indices, preserving firm equity valuation support. |
| Q2 2031 | 35.01 | +2.35% | +70.26% | First-half execution demonstrates dependable organic revenue compounding, anchored by unyielding customer retention across global sovereign defense programs. Expanding adoption in infrastructure and life sciences provides ongoing revenue diversification, driving modest quarterly equity appreciation. |
| Q3 2031 | 35.72 | +2.03% | +73.71% | The forecast horizon concludes with the enterprise model fully transitioned to cloud subscriptions and generating over two billion euros in annual free cash flow. Durable intellectual property and irreplaceable engineering lock-in secure normalized valuation permanence. |
The fundamental investment case rests on the widening divergence between optical headline revenue stagnation and underlying economic compounding. As enterprise clients systematically transition from upfront perpetual licenses to ratable cloud subscriptions, recurring software revenue now exceeds eighty percent of turnover, generating over 1.4 billion euros in annual free cash flow. Elevated customer switching barriers across aerospace and sovereign defense platforms guarantee unyielding pricing power and renewal durability. While persistent capital expenditure cuts by European automotive manufacturers and integration frictions across clinical life sciences platforms cap near-term multiple expansion, valuation sensitivity is heavily asymmetric, anchored by an unencumbered balance sheet and high cash conversion.
Key insights
- Contractual switching moats in parametric geometry and certified airframe mockups prevent seat cancellations, ensuring software annuities persist regardless of broader European industrial downturns.
- Transition accounting temporarily depresses reported sales growth, but expanding subscription run rates compound operating cash flow to fund anti-dilutive buybacks and strategic bolt-ons.
- Recent margin expansion reflects research cost restraint alongside business mix improvements, requiring investors to underwrite disciplined operational execution rather than unproven artificial intelligence windfalls.
The company looks like a slow-growing business on the surface, but underneath it is shifting toward reliable subscription software. Industrial customers cannot easily replace its design systems without risking factory disruptions, creating dependable recurring cash. Although weak European car production and slow biotech spending delay quick sales growth, strong cash generation and a cash-rich balance sheet protect investors against severe downturns while earnings compound quietly over time.
Key insights
- Deep customer habit and complex engineering data make replacing core software practically impossible for major aerospace manufacturers.
- Subscription accounting makes early revenue look flat while quietly building an expanding, highly predictable foundation of cash flow.
- Steady earnings growth depends on disciplined cost management and steady customer renewals rather than sudden technological breakthroughs.
Deep Dive
Market consensus views the company as an impaired legacy European software champion whose growth engine has permanently stalled. Fixated on sluggish European automotive capital expenditures, ongoing contract delays within the clinical life sciences business, and consecutive guidance resets, the crowd prices the equity at cyclical trough multiples, assuming generative artificial intelligence will commoditize seat-based engineering design tools.